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Abstract
In this study, the efficacy of ovine antimicrobial anionic peptide (AP) was assessed in a lamb model of acute pneumonia. A
single intratracheal dose of the peptide, H-DDDDDDD-OH (0.5 mg) reduced pulmonary inflammation and the concentration of
Mannheimia (Pasteurella) haemolytica in infected lung tissue. Administration of H-DDDDDDD-OH after infection was more
effective in reducing the consolidation and lesion scores at the deposition site than its administration prior to infection. Hence,
the in vivo effectiveness of AP suggests that it may have applications in the treatment of pulmonary infections. Further studies
are needed to confirm these findings and also to determine the optimal doses and intervals of H-DDDDDDD-OH therapy.
© 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
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1. Introduction
Antimicrobial peptides constitute an important in-
nate defense against microbial infections of mucosal
surfaces. Antimicrobial peptides found in mammals
belong to families of anionic peptides (APs), defensins
(including - and -defensins), and cathelicidins [1–4].
These peptides have broad-spectrum antimicrobial
activities against both Gram-positive and Gram-nega-
tive bacteria, fungi, mammalian cells and enveloped
viruses.
Anionic peptides were originally detected in sheep
and three small peptides, H-GADDDDD-OH, H-
GDDDDDD-OH and H-DDDDDDD-OH, were iso-
lated from ovine surfactant extracts [4]. Monoclonal
antibodies prepared to AP were used to detect AP in
the bronchoalveolar lavage fluid and respiratory epithe-
lial cells of sheep [5], cattle, and humans [6]. APs occur
in mM concentrations [5], require zinc as a cofactor for
antimicrobial activity [4] and peptides (natural and
synthetic) are rapidly antimicrobial against both Gram-
positive and Gram-negative organisms (range 0.15–
1.06 mM).
Since APs are effective against a broad spectrum of
pathogens in vitro, they may be possible candidates for
the treatment of airway infections. To test this, we
established a model of acute pneumonia in lambs using
the ovine respiratory pathogen Mannheimia (Pas-
teurella) haemolytica. With this model, we addressed
whether administration of H-DDDDDDD-OH after
infection or prior to infection was effective in prevent-
ing experimentally induced lung disease and then, if
there was a difference between the timing of
administration.
* Corresponding author. Tel.: +1-515-6637534; fax: +1-515-
6637458.
E-mail address: kbrogden@nadc.ars.usda.gov (K.A. Brogden).
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2. Material and methods
2.1. Preparation of surfactant diluent
Ovine pulmonary surfactant was prepared as previ-
ously described [7] and used as a diluent for both
bacterial inoculum and peptide suspensions to maximize
pulmonary spreading of organisms and lesion penetra-
tion of the peptide [8,9]. Briefly, lyophilized surfactant
(103.20 mg) and ZnCl2 (0.54 mg) were suspended in
saline (412.8 ml) to a final concentration of 0.25 mg/ml,
10 and 140 mM respectively. This diluent was not
antimicrobial for M. haemolytica serovar 1, strain 82-25
even after 4 h.
2.2. Peptide synthesis
H-DDDDDDD-OH was synthesized by Multiple
Peptide Systems (San Diego, CA) using Merrifield resins
and standard t-BOC chemistry in combination with
simultaneous multiple peptide synthesis (SMPS or ‘tea-
bag’ methodology). Cyclohexyl was used as a side-chain
protecting group for aspartic acid. The peptides were
side-chain deprotected and cleaved from the solid sup-
port by acidolysis with HF. Peptides were purified by
HPLC, characterized by analytical HPLC and by
plasma desorption mass spectral analysis on a Biolon 20
Mass Analyzer and lyophilized. Peptides were 95–99%
pure and verified by amino acid analysis.
H-DDDDDDD-OH (50.20 mg) was suspended in 100
ml of diluent and mixed overnight at 4°C. Final concen-
trations of surfactant, ZnCl2, and H-DDDDDDD-OH
were 0.25 mg, 10 M, and 0.5 mg/ml, respectively. The
suspension (0.1 ml) was plated onto trypticase soy agar
with 5% defibrinated sheep blood to confirm sterility.
2.3. Bacterial inoculum
M. haemolytica serovar 1 strain 82-25, originally
isolated from sheep with pneumonia, was grown
overnight on blood agar containing trypticase soy agar
with 5% defibrinated sheep blood (Lab Supply Co., Des
Moines, IA). The overnight growth was transferred to
35 ml of tryptose broth (Difco Laboratories, Detroit,
MI) and incubated at 37°C for 3 h on a magnetic stirrer.
The culture was centrifuged at 7000 rpm for 10 min at
4°C, suspended in 140 mM NaCl and adjusted in a
spectrophotometer (0.108 OD; 600 nm, Coleman model
35, Bacharach Instrument Co.) to contain approxi-
mately 1.0×108 CFU/ml. The bacterial cells in 150 ml
of suspension were then pelleted by centrifugation at
10 000×g for 10 min at 4°C and suspended in 150 ml
of diluent. An exact viable bacterial concentration was
determined by standard plate count on blood agar.
The inoculum was kept on ice throughout the proce-
dure.
2.4. Lambs
Seventeen 8-month old lambs of approximately 150
pounds, were housed in isolation rooms and treated by
methods approved by the American Association for
Accreditation of Laboratory Animal Care and the Na-
tional Animal Disease Center Animal Care and Use
Committee. Previous exposure of lambs to M.
haemolytica serovar 1 was determined with an enzyme-
linked immunosorbent assay (ELISA) by measuring
serum antibody titre to a whole cell lysate (100 l of
lysed 1.0×108 CFU/ml suspension prepared in 0.05 M
Tris buffer, pH 7.0) as previously described [10]. Lambs
had antibody titres to M. haemolytica strain 82-25 lysate
(log2 titer 10.300.4 SE) indicating previous natural
exposure. Ruminants have M. haemolytica as a part of
their normal flora and these titres are comparable to
those previously reported in naturally reared lambs
[10,11]. Vaccinated sheep, used as a positive ELISA
control, had a titre to M. haemolytica strain 82-25 lysate
(log2 titre 15.7) and normal sheep, used as a negative
ELISA control, also had a titre to M. haemolytica strain
82-25 lysate (log2 titre 8.9).
2.5. Inoculation procedure
The lambs were randomized to seven groups to assess
the ability of H-DDDDDDD-OH to treat (Groups 2–4)
or prevent (Groups 5–7) experimental infection (Table
1). Lambs were lightly sedated with 20 mg xylazine
(Rompun, Bayer Corp., Shawnee Mission, KS). A small
plastic tube was inserted into the oral cavity and served
as a speculum. A bronchoscope (Model VFS-2; Schott
Fiber-optics, Inc., Southbridge, MA) was inserted into
the tube and lidocaine (0.5 ml of 2% lidocaine hydro-
chloride, TechAmerica, Group, Inc., Elwood, KS) was
administered to ease the ‘scope past the larynx. The tip
of the bronchoscope was moved to the dorsum of the
caudal portion of the cranial lobe of the right lung
(pulmonary deposition site) in each animal for deposi-
tion of inocula [10]. After inoculation, the effects of
xylazine were reversed by intravenous injection of 100
mg tolazoline HCl (Tolazine, Lloyd Laboratories,
Shenandoah, IA).
Lambs in Group 1 (n=1) and Group 2 (n=2)
received 10 ml of diluent. Lambs in Groups 3 (n=3)
and 4 (n=3) received 10 ml diluent containing 2.5×108
CFU/ml M. haemolytica. At 24 h post inoculation,
lambs in Groups 2 and 4 received 10 ml diluent contain-
ing 0.5 mg/ml H-DDDDDDD-OH, and lambs in
Groups 1 and 3 only received 10 ml diluent.
Lambs in Groups 5 (n=3) and 7 (n=3) received 10
ml diluent containing 0.5 mg/ml H-DDDDDDD-OH,
and lambs in Group 6 (n=3) received 10 ml diluent. At
24 h post inoculation, lambs in Group 5 received 10 ml
diluent, and lambs in Groups 6 and 7 received 10 ml
diluent containing 2.5×108 CFU/ml M. haemolytica.
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2.6. Necropsy
At 48 h post inoculation, all lambs were euthanized
with pentobarbital and exsanguinated. At necropsy, the
lungs were evaluated grossly, and total lung involve-
ment was calculated as the sum of the consolidated
portions of each lobe multiplied by the percent each
lobe contributed to the total lung volume. Using this
system, the lobar contributions were right cranial 15%,
right middle 8%, right caudal 29%, accessory 4%, left
cranial 16% and left caudal 28% [12]. Pieces of tissue
were taken from the pulmonary deposition site and
fixed in 10% neutral buffered formalin solution, dehy-
drated and cleared, embedded in paraffin, sectioned
and stained with hematoxylin and eosin stains. Pieces
of tissue were also collected for quantitative bacterial
culture as previously described [10].
Lung sections were scored according to the type of
infiltrate (lymphocyte, neutrophil, and macrophage) as
well as to the extent of necrosis, haemorrhage, collapse,
and fibrosis. Scores ranged from 0 (no changes) to 4
(most severe changes) for each category. The final score
was a total of the individual scores for each animal (less
the score for lymphocyte infiltrates and degree of
collapse).
3. Results
In this study, we wanted to answer three basic ques-
tions. First, is administration of H-DDDDDDD-OH
after infection effective in treating experimentally in-
duced lung disease? Overall, administration of peptide
after M. haemolytica infection (Group 4) reduced pul-
monary inflammation and the concentration of organ-
isms in infected lung tissues (Figs. 1 and 2 and Table 2).
Untreated lambs in Group 3 had 45.0% mean consoli-
dation (range 5–80%) at the pulmonary deposition site
(Fig. 1C). Lesion scores varied from 4 to 11. Lambs in
Group 3 had moderate to severe acute suppurative
bronchitis/pneumonia, moderate collapse and minimal
macrophage infiltration. One lamb had severe necrosis
and haemorrhage. Numerous colonies of bacteria were
also seen. In contrast, infected lambs in Group 4
treated with H-DDDDDDD-OH had substantially less
inflammation (Fig. 1D) and concentrations of organ-
isms in the lungs (Table 2). Lambs had 15.0% mean
consolidation (range 5–25%) at the pulmonary deposi-
tion site and lesion scores varied from 2 to 3. There
were minimal multifocal peribronchial lymphocytes,
minimal to mild multifocal suppurative bronchitis/
pneumonia and minimal to marked collapse (Fig. 2D).
Bacterial counts were 6.8 log10 (CFU/ml +1) in Group
3 vs. 2.3 log10 (CFU/ml +1) in Group 4.
Second, is administration of H-DDDDDDD-OH
prior to infection effective in preventing experimentally
induced lung disease? The results between these groups
were nearly identical (figures not shown) and there were
no differences between Groups 6 and 7 for percent
consolidation, lesion score and organisms in consoli-
dated lesions. Lambs in Group 6 had 25% mean consol-
idation (range 15–40%) at the pulmonary deposition
site, and lesion scores ranged from 4 to 7, whereas
lambs in Group 7 had 45.0% mean consolidation (range
30–65%) at the pulmonary deposition site and histo-
pathology scores ranged from 4.5 to 6. In both groups,
there was minimal to marked multifocal peribronchial,
lymphocytic infiltration, minimal to moderate multifo-
cal suppurative, bronchitis/pneumonia and minimal to
moderate collapse. Bacterial counts in these lambs did
not differ (4.6 log10 (CFU/ml +1) in Group 6 vs. 4.9
log10 (CFU/ml +1) in Group 7).
Thirdly, is there a difference between administration
of H-DDDDDDD-OH after infection and administra-
tion prior to infection in treating experimentally in-
duced lung disease? The results showed that the
administration of H-DDDDDDD-OH after experimen-
tal infection resulted in less % consolidation and a
much lower lesion score than administration of H-
DDDDDDD-OH prior to infection.
4. Discussion
Antibiotics are commonly used to treat airway infec-
tions or pneumonia. However, many antibiotics cur-
rently used have problems that limit their effectiveness.
Table 1
Experimental design to assess the potential of H-DDDDDDD-OH to
treat or prevent M. haemolytica serovar 1 experimental infection in
lambs
Second IT (10 ml)First ITa (10 ml)No. lambsGroup
Control group
Diluentb1 1 Diluent
Treatment groups
H-DDDDDDD-OHcDiluent22
33 M. haemolyticad Diluent
4 3 M. haemolytica H-DDDDDDD-OH
Preention groups
2 H-DDDDDDD-OH Diluent5
M. haemolytica6 Diluent3
37 H-DDDDDDD-OH M. haemolytica
a Intratracheal procedure to deposit inocula into the right cranial
lobe of the lung.
b Diluent containing 0.25 mg/ml ovine pulmonary surfactant and
10 mM ZnCl2 in 140 mM NaCl.
c 0.5 mg/ml H-DDDDDDD-OH in 10 ml diluent. The final dose
was 5.0 mg/lamb.
d 1.0×108 CFU/ml M. haemolytica serovar 1 strain 82-25 in 10 ml
of diluent. The final challenge was 1.0×108 CFU.
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Fig. 1. Lungs of lambs showing the deposition sites: (A) group 1 first received diluent followed by diluent; (B) group 2 first received diluent
followed by H-DDDDDDD-OH; (C) group 3 first received M. haemolytica followed by diluent; (D) group 4 first received M. haemolytica followed
by H-DDDDDDD-OH. No lesions were seen after deposition of diluent (A) or diluent with H-DDDDDDD-OH (B). Infection control lesions in
the anterior part of the right cranial lobe (C) consisted of areas of consolidation with necrosis and hemorrhage. The lesion is significantly reduced
24 h after a single treatment with H-DDDDDDD-OH (D).
Therefore, the search continues for new antibiotics that
are active in the complex pulmonary milieu, are fast
acting and broad-spectrum, do not induce bacterial
resistance and have limited side effects. APs may be
good candidates. In addition to the properties described
above, they are easy to synthesize in large quantities,
generally have activity in both low and high ionic
strength conditions and have very few side effects.
APs have been demonstrated readily both in respira-
tory epithelium and in mucosal secretions at concentra-
tions that are antimicrobial [6]. These findings support
the hypothesis that APs not only contribute to the
microenvironment in the pulmonary milieu but also
function as adjuncts to the other innate and adaptive
host defense elements of the mammalian airway. Since
H-DDDDDDD-OH was quite effective in vitro against
M. haemolytica (MIC 0.08 mM), one might speculate
that this AP might be used to treat or prevent pul-
monary infections. To test this, we established a model
of acute pneumonia in lambs using M. haemolytica.
Overall, diluent alone and diluent containing H-
DDDDDDD-OH were both well tolerated (Groups
1, 2, and 5) and did not induce any changes. Lambs in
these groups had little (1–5%) consolidation at the
pulmonary deposition site. The lesion score was 2, and
lesions were characterized as minimal to mild multifo-
cal peribronchial, lymphocytic infiltration and minimal
multifocal, suppurative bronchitis and mild collapse.
One lamb in Group 5, however, had 50% consolidation
of the right cranial lobe and a histopathology score of
9. This lamb had severe diffuse peribronchial
lymphocytes, mild multifocal, suppurative bronchitis,
marked diffuse fibrosis, marked diffuse fibrosis and
mild mineralization, and lesions characteristic of my-
coplasma or lungworms and not of M. haemolytica. M.
haemolytica was not isolated from the pulmonary depo-
sition site of any lambs in these groups.
In infected lambs, a single bronchial instillation of
5.0 mg H-DDDDDDD-OH reduced the concentration
of bacteria in consolidated pulmonary tissues. Treat-
ment with a higher dose of H-DDDDDDD-OH or with
multiple doses of H-DDDDDDD-OH may have fur-
ther reduced or eliminated local inflammation and or-
ganisms in the pulmonary deposition site. The 5.0 mg
was an arbitrary starting concentration; however it
appears to be within the range of detectable activity.
Administration of peptide before infection did not
prevent pulmonary inflammation or reduce the concen-
tration of organisms in infected lung tissues. The reason
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for this is not known. It is quite possible that during the
period after peptide administration and before experi-
mental infection, H-DDDDDDD-OH was removed by
normal physiological mechanisms. The concentration
and effectiveness of AP will depend upon the availabil-
ity of zinc; co-mixture with serous fluid or plasma; rate
of clearance by lymphatic, circulatory, and urinary
systems, degradation by pulmonary oligopeptidases, or
uptake by epithelial cells.
In conclusion, a single dose of H-DDDDDDD-OH
reduced the concentration of bacteria in this model of
infection and administration of peptide after infection
was more effective than prior to infection. The in vivo
effectiveness of AP suggests they may have applications
in the treatment of pulmonary infections. However,
further studies are needed to confirm these findings and
also determine the optimal doses and intervals of H-
DDDDDDD-OH therapy.
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Fig. 2. Photomicrographs of pulmonary tissue showing sections of bronchiole and surrounding pulmonary alveoli: (A) the bronchiolar wall in
Group 1 contained relative few lymphocytes. The bronchiolar lumen and the alveoli also lacked significant infiltrates of cells and exudate; (B) the
bronchiolar wall in Group 2 contained minimal-to-mild infiltrates of lymphocytes, but there was no acute inflammatory response in the
bronchioles or alveoli; (C). lumens in Group 3 contained large numbers of neutrophils, cell debris, and proteinaceous exudate (arrow); (D) the
bronchiolar walls in Group 4 contained moderate numbers of lymphocytes, but there was no acute inflammatory response.
Table 2
Pathologic changes and concentration of M. haemolytica serovar 1, ovine strain 82–25 in lamb lung tissue
Lung lesion scorePercent lung consolidationGroup Log10 CFU M. haemolytica/g consolidated tissue
1 2.01.0 0.0
2 2.0 (0.0)3.0 (2.0) 0.0
6.8 (2.2)7.0 (2.1)3 45.0 (21.8)
15.0 (5.8) 2.3 (0.3) 2.3 (1.4)4
26.5 (23.5)5 5.0 (4.0) 0.0
4.6 (0.9)5.3 (0.9)25.0 (7.6)6
45.0 (10.4)7 4.8 (0.6) 4.9 (0.5)
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